NASDAQ Careers: Find a Job Now
Web NASDAQ.com
Search
Save my stocks for next time

Symbol List ViewsSymbol List Views

Stock DetailsStock Details

Stock DetailsCHARTS

Stock DetailsCOMPANY NEWS

Stock DetailsSTOCK ANALYSIS

Stock DetailsFUNDAMENTALS

Stock DetailsHOLDINGS

GILD: Stock Quote & Summary Data

$ 46.39 0.13 0.28%
Nov. 20, 2009 Market Closed
Update Quotes: . Updates every 7 Seconds.
Gilead Sciences, Inc.
GILD | Gilead Sciences, Inc. | Common Stock | Market : NASDAQ-GS

Last Sale
Change Net / %
Best Bid / Ask
1y Target Est: $ 56.00
Today's High / Low  / 
Share Volume
50 Day Avg. Daily Volume 7,987,362
Previous Close $ 46.52
52 Wk High / Low $ 53.28 / $ 39.37
Shares Outstanding 904,261,000
Market Value $ 41,948,667,790
P/E Ratio 18.12
Forward P/E (1yr) 14.86
Earnings Per Share $ 2.56
Annualized Dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield N/A
Beta 0.62
NASDAQ Official Open Price: $ 46.27
Date of NASDAQ Official Open Price: Nov. 20, 2009
NASDAQ Official Close Price: $ 46.39
Date of NASDAQ Official Close Price: Nov. 20, 2009

 Intraday Chart

5d | 1m | 6m | 12m | More Charting

Have a Question About GILD?

Ask your question about about Gilead Sciences, Inc. (GILD) by typing it in the box below. You'll get direct responses from other members of the NASDAQ Answers community!

Hot Topics in NASDAQ Answers

The most popular questions & answers in the
NASDAQ Answers Community:


 Company Description (as filed with the SEC)

Gilead Sciences, Inc. (Gilead, we, us or our), incorporated in Delaware on June 22, 1987, is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Our mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, we have operations in North America, Europe and Australia. To date, we have focused our efforts on bringing novel therapeutics for the treatment of life-threatening diseases to market. We continue to seek to add to our existing portfolio of products through our internal discovery and clinical development programs and through an active product acquisition and in-licensing strategy.  ... More ...  

Get ETF News, Commentary, Tools & more...

Visit the new NASDAQ.com ETFs hub Now

 Company News for GILD

Now's a Great Time to Invest -- So Don't Blow It Like This
- The Motley Fool  11/19/2009 3:32PM
5 Stocks Geared for Growth
- The Motley Fool  11/19/2009 3:30PM
5 Stocks Making Cash
- The Motley Fool  11/18/2009 1:21PM
Gilead Sciences To Present At The Lazard Capital Markets 6TH Annual Healthcare Conference; Webcast At 2:10 PM ET
- RTT News  11/17/2009 11:10AM
A Big Upgrade for Sanofi-Aventis
- The Motley Fool  11/17/2009 10:04AM
2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- PR Newswire  11/16/2009 6:01PM
The Worst Stocks to Buy Today
- The Motley Fool  11/16/2009 4:03PM
 

Consensus Recommendation


Analyst Info

Annual EPS Est: $ 2.76
Quarterly EPS Est: $ 0.81
PEG Ratio: 1.00
Mean Recommendation:
View Summary/View All
1.84